Scott T. Tagawa, M.D., MS
After developing an interest in fighting cancer in medical school, I was fortunate to work with and learn from leadersin the field of genitourinary oncology during internship, residency, and fellowship training. I feel fortunate to have joined the faculty at Weill Cornell to work with renowned mentors and colleagues in both medical oncology and urology. Together I am confident we will make progress towards increasing the cure rate and decreasing suffering from these diseases.
Scott T. Tagawa, MD was initially appointed to the faculty of Weill Cornell Medical College in April, 2007 as Assistant Professor of Medicine and Urology and Assistant Attending Physician in the Division of Hematology and Medical Oncology. He joined the Genitourinary Oncology Program within the Solid Tumor Service in the Division of Hematology and Medical Oncology.
After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. After completing his Internship and Residency training there, he was Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology from, being appointed Chief Fellow for his final two years. In August 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center he took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medical College in 2007. His research has involved clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, he leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He also serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology and Chair of the Clinical Study Evaluation Committee. He was promoted to Associate Professor of Clinical Medicine and Urology in 2013. He is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a member of the Genitourinary Committee. He currently serves as a member of the scientific committee for the American Society of Clinical Oncologists.
A summary of Dr. Tagawa's Education, Training and/or Faculty Appointments is listed as following:
Georgetown University, Washington D.C. B.S.; 1993.
University of Southern California School of Medicine, Los Angeles, CA. M.D.; 1998.
Internship, Internal Medicine. University of Southern California Department of Medicine; June 1998 - June 1999.
Residency, Internal Medicine. University of Southern California Department of Medicine; July 1999 - June 2001.
Chief Resident, University of Southern California Department of Medicine, Los Angeles, CA.; July 2001 -June 2002.
Fellowship, Combined program in Hematology and Oncology. University of Southern California Department of Medicine, Divisions of Hematology and Oncology; July 2002 - June 2005.
Chief Fellow, Hematology; 2003-04.
Chief Fellow, Oncology; 2004-05.
Weill Cornell Graduate School of Medical Sciences, Masters of Science in Clinical Investigation; 2010.
Assistant Professor of Medicine, Division of Hematology & Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY; August 2005 - March 2007.
Director, Medical Oncology, Deane Prostate Health & Research Center, Mount Sinai Hospital; August 2005 - March 2007.
Director, Genitourinary Oncology, Division of Hematology & Oncology, Department of Medicine, Mount Sinai School of Medicine; January 2006 - March 2007.
Associate Director, Hematology/Oncology Fellowship Program, Mount Sinai School of Medicine, New York, NY; January 2006 - March 2007.
Assistant Professor of Medicine & Urology, Weill Cornell Medical College, New York, NY; 2007 - 2012.
Medical Director, Genitourinary Oncology Research Program; July 2010 – Present.
Associate Professor of Clinical Medicine & Urology, Weill Cornell Medical College, New York, NY; 2013 - present
Attending Staff Physician, Los Angeles County University of Southern California Medical Center, Los Angeles, CA.; July 2001 - June, 2005.
Assistant Attending Staff Physician, Mount Sinai Medical Center, New York, NY; September 2005 -March 2007.
Assistant Attending Physician, NewYork-Presbyterian Hospital, New York, NY; April 2007 - 2012.
Associate Attending Physician, NewYork-Presbyterian Hospital, New York, NY; 2013 - present.
American Society of Clinical Oncology
American Society of Hematology
American College of Physicians
American Urologic Association
Alliance for Clinical Trials in Oncology (formerly CALGB)
American Association for Cancer Research
Urologic Oncology (Editor, Seminars Section)
Therapeutic Advances in Medical Oncology
Frontiers in Genitourinary Oncology
Annals of Oncology
Journal of Tumor
American Journal of Clinical and Experimental Urology
Ad hoc reviewer:
Journal of Urology
American Journal of Hematology
OncoTargets and Therapy
Clinical Cancer Research
International Journal of Cancer
Medical & Surgical Urology
Journal of Clinical Oncology
British Journal of Urology International
Advances in Urology
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.
- AETNA [HMO]
- AETNA [PPO]
- AETNA [Medicare]
- Aetna - Weill Cornell [POS]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- GHI [CBP]
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Insurance Plan of NY (HIP)
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Medicare [Medicare]
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care
- United Health Care [Medicare]
- United Health Care [Community Plan]
- VNSNY CHOICE Medicare [Medicare]
- VNSNY CHOICE Medicare [HMO]
Articles in professional peer-reviewed journals
Tagawa ST, Lee P, Snively J, Boswell W, Ounparseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for stage IV melanoma. Cancer 98: 144-154, 2003.
Israel V*, Tagawa ST*, Snyder T, Jeffers S, Raghavan D. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer. Investigational New Drugs 2004; 22: 291-297. *Co-first authors
Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in stage IV melanoma. Cancer 2006; 106: 1353-7.
Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. Subclinical hemostatic activation and surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int 2008; 102(9): 1086-91.
Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH. Anti-Prostate Specific Membrane Antigen-based Radioimmunotherapy for Prostate Cancer. Cancer 2010; 116(4 suppl): 1075-83.
Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010; 10: 27-29.
Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin Plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer. Urol Oncol 2011 Nov-Dec;29(6):676-81. Epub 2010 May 7. PubMed PMID: 20451413.
Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ, Nanus DM. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma (New York Cancer Consortium trial NCI 6981). Am J Clin Oncol 2011 Oct;34(5):443-8. Epub 2010; Sep 24. PubMed PMID: 20881475.
Beltran H, Robinson BD, Tagawa ST. Primary Squamous Cell Carcinoma of the Urinary Bladder Presenting as Peritoneal Carcinomatosis. Adv Urol 2010; article ID 179250. Epub 2010 Jun 27. PubMed PMID: 20672052; PubMed Central PMCID: PMC2905698
Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M , Yang X, Oliner KS, Anderson A, Zhu M,Kabbinavar K. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 2011; 108(5): 679-86. doi: 10.1111/j.1464-410X.2010.09947.x. Epub 2010 Dec 13. PubMed PMID: 21156020.
Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P. PET/CT imaging and radioimmunotherapy of prostate cancer. Sem Nuc Med 2011; 41: 29-44.
Beltran H, Beer T, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: Efficacy and safety. European Urology 2011; 60(2): 279-90. http://dx.doi.org/10.1016/j.eururo.2011.04.038
Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012:973820. Epub 2011 Jul 17. PubMed PMID: 21811498; PubMed Central PMCID: PMC3145341.
Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. Cancer Res 2011 Sep 15;71(18): 6019-29. Epub 2011 Jul 28. PubMed PMID: 21799031; PubMed Central PMCID: PMC3354631.
Beltran H, Rickman DS, Park K, Sboner A, MacDonald TY, Wang Y, Chae SS, Sheikh K, Terry S, Tagawa ST, Dhir R, Nelson J, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta K, Chinnaiyan A, Wang Y, Collins C, Gleave M, Demichelis F, Nanus DM, Rubin MA. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery 2011, Nov;1(6):487-95. PubMed PMID: 22389870; PubMed Central PMCID: PMC3290518.
Smith MJ, Akhtar NH, Tagawa ST. The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer. Prostate Cancer 2012, 2012: 280278. Epub 2012 Apr 24. PubMed PMID: 22619727; PubMed Central PMCID: PMC3348643.
Kosuri S, Akhtar NH, Smith MJ, Osborne J, Tagawa ST. Review of salvage therapy for biochemically recurrent prostate cancer: The role of imaging and rationale for systemic salvage targeted anti-prostate specific membrane antigen radioimmunotherapy. Adv Urol 2012: 921674. Epub 2012 May 28. PubMed PMID: 22693495; PubMed Central PMCID: PMC3368159.
Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device. PLoS One 2012; 7(4): e35976. Epub 2012 Apr 27. Erratum in: PLoS One. 2012;7(7):doi/10.1371/annotation/9d3d22ed-dc5a-4484-9254-1584864f4aac. PubMed PMID: 22558290; PubMed Central PMCID: MC3338784.
Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate specific membrane antigen imaging. Urol Oncol 2012 May 30. [Epub ahead of print] PubMed PMID: 22658884; PubMed Central PMCID: PMC3461099.
Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R. Randomized phase II study of Danusertib (formerly PHA-739358) in patients with metastatic Castration Resistant Prostate Cancer (CRPC) after docetaxel failure. BJU Int 2012 Aug 29. doi: 10.1111/j.1464-410X.2012.11404.x. [Epub ahead of print] PubMed PMID: 22928785.
Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joual A, Scherr DS, Gonen M. Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. Eur Urol 2012 Jun 16. [Epub ahead of print] PubMed PMID: 22727174.
Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF. Accurate Pre-operative Prediction of Non-Organ Confined Bladder Urothelial Carcinoma at Cystectomy. BJU Int. 2012 Jul 13. doi: 10.1111/j.1464-410X.2012.11370.x. [Epub ahead of print]
Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU Int. 2012 Jul 19. doi: 10.1111/j.1464-410X.2012.11356.x. [Epub ahead of print]
Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski T, Reddy M, Cornfeld M, Eisenberger M. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castrate-resistant prostate cancer. Invest New Drugs 2012, Jul 25. [Epub ahead of print] PubMed PMID: 22828917.
Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? World J Urol 2012 Jul 26. [Epub ahead of print] PubMed PMID: 22832587.
Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joual A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, Shariat SF. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. Eur Urol 2012 Jul 20. [Epub ahead of print] PubMed PMID: 22877503.
Beltran H, Yelensky R, Frampton G, Park K, Downing S, MacDonald TY, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA. Targeted Next Generation Sequencing (NGS) of Advanced Prostate Cancer Using Formalin Fixed Paraffin Embedded Tissue Identifies New Therapeutic Targets. Eur Urol 2012 Sep 5. pii: S0302-2838(12)01006-8. doi: 10.1016/j.eururo.2012.08.053. [Epub ahead of print] PubMed PMID: 22981675.
Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; for the Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 2012 Sep 3. doi: 10.1111/j.1464-410X.2012.11433.x. [Epub ahead of print] PubMed PMID: 22938654.
Diamond ES, Lee GY, Akhtar NH, Kirby B, Giannakakou P, Tagawa ST, Nanus DM. Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012; 2: 131. doi: 10.3389/fonc.2012.00131
Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky M, Mosquera JM, Rubin M, Nanus DM. Challenges in Recognizing Treatment Related Neuroendocrine Prostate Cancer. J Clin Oncol, 2012 Nov 19 [Epub ahead of print] PubMed PMID: 23169519
Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y
Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ,
Tagawa ST, Zerbib M, Karakiewicz PI, Shariat SF. Risk-stratification of pT1-3N0 patients
after radical cystectomy for adjuvant chemotherapy counseling. Br J Cancer 2012 Nov 20;
107(11):1826-32. doi: 10.1038/bjc.2012.464
Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S,
Bismar TA, Erbersdobler A, Nanus DM, Rubin MA. Concurrent AURKA and MYCN gene
amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Neoplasia 2013; 15(1): 1-10. PMID 23358695
Akhtar NH, Osborne J, Fareedy SB, Tagawa ST. PSMA-targeted dendrimers (WO2012078534): A Patent Evaluation. Expert Opin Ther Patents 2013; Epub ahead of print 2013 April 13 (doi:10.1517/13543776.2013.789501)
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Pandit-Taskar N, Scher HI, Bander NH, Nanus DM. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013; 19(18): 5182-91. doi: 10.1158/1078-0432.CCR-13-0231 [Epub 2013 May 28] PMID: 23714732
Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R. Tolerability, Safety and Pharmacokinetics of Ridaforolimus in combination with Bicalutamide in patients with asymptomatic, metastatic Castration Resistant Prostate Cancer (CRPC). Cancer Chemother Pharmacol 2013 Aug 7 [Epub ahead of print] PMID: 23921574
Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, Vallabhajosula S,
Goldsmith SJ, Nanus DM, Bander NH. Bone marrow recovery and subsequent
chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal
antibody J591 in men with metastatic castration-resistant prostate cancer. Front Oncol
2013 Aug 26;3:214. doi: 10.3389/fonc.2013.00214.
Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol. 2013 Sep 3. [Epub ahead of print]
Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Matsumoto K, Ikeda M, Dalpiaz O, Zigeuner R, Aziz A, Fritsche HM, Deliere A, Raman JD, Bensalah K, Al-Matar B, Gakis G, Novara G, Klatte T, Remzi M, Comploj E, Pycha A, Rouprêt M, Tagawa ST, Chun FK, Scherr DS, Vickers A, Shariat SF. Predictors of survival in patients with disease recurrence following radical nephroureterectomy. BJU Int. 2013 Jul 19. doi: 10.1111/bju.12369. [Epub ahead of print]
Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 2013 Nov 18. doi: 10.1002/cncr.28477. [Epub ahead of print]
Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin C-C, Mahoney J, Modi S, Lee P, Ernstoff MS, Su W-C, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA. An Open-Label, Single-Arm Phase II Trial of the Polo-Like Kinase Inhibitor Volasertib (BI 6727) in Patients with Locally Advanced or Metastatic Urothelial Cancer. Cancer 2013 Dec 11. doi: 10.1002/cncr.28519. [Epub ahead of print]
Gakhar G, Navarro VA, Jurish M, Yu G, Tagawa ST, Akhtar NH, Seandel M, Geng Y, Liu H, Bander NH, Giannakakou P, Christos PJ, King MR, Nanus DM. Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow. PLoS ONE 8(12): e85143. doi:10.1371/journal.pone.0085143
Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating
Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical
Potential. Mol Diagn Ther. 2014 May 9. [Epub ahead of print]
Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, Tagawa ST. Microtubule inhibitor
based antibody-drug conjugates for cancer therapy. OncoTargets and Therapy 2014; in press
Galletti G, Matov A, Beltran H, Fontugne J, Mosquera JM, Cheung C, MacDonald TY, Sung M, O’Toole S, Kench JG, Chae SS, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS. ERG Induces Taxane Resistance in Castration-Resistant Prostate Cancer. Nature Communications 2014, accepted
Books, book chapters, invited reviews, and editorials.
Tagawa ST. Thrombosis in cancer: A review of epidemiology, plasma markers of hemostatic activation, fibrinolysis, and angiogenesis, and the potential use of heparins. Recent Res Devel Cancer 2004; 6(2): 295-310.
Tagawa ST, Hamid O, Skinner E, Kumar P. Uncommon Cancers of the Prostate. In Textbook of Uncommon Cancers, 3rd Ed. Raghavan D et al. Eds. Wiley & Sons, Ltd, 2006.
Arnason J, Tagawa ST, Bander NH. New and newer vascular targets in oncology. Oncology 2007; 21: 1376-80.
Tagawa ST. Editorial Comment: “Phase II trial of paclitaxel, carboplatin, and gemcitabine in patients with locally advanced carcinoma of the bladder”. J Urol 2008; Oct 16 [E Pub Ahead of Print]
Tagawa ST. Editorial Comment: “Sequential us of sorafenib and sunitinib in a series of 90 consecutive patients with renal cell carcinoma”. J Urol 2009 Sep;182(3):906. Epub 2009 Jul 17. PubMed PMID: 19616231.
Tagawa ST. Editorial Comment: “Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Consortiuim”. J Urol September 2009;182: 90.
Beltran H, Nanus DM, Tagawa ST. Beyond the Abstract - Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. UroToday.com, July 30, 2010. http://www.urotoday.com/3341/browse_categories/beyond_the_abstract/beyond_the_abstract__carboplatin_plus_paclitaxel_therapy_after_docetaxel_in_men_with_metastatic_castrate_resistant_prostate_cancer_by_himisha_beltran_md_et_al07302010.html#showcomments
Bander NH, Vallabhajosula S, Goldsmith SJ, Tagawa ST, Nanus DN. Targeted Radionuclide Therapy for Prostate Cancer. In Targeted Radionuclide Therapy. Speer TW Ed. Lippincott Williams & Wilkins, 2010.
Akhtar NH, Tagawa ST. Editorial Comment: “The Value of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy”. J Urol 2011 Jan;185(1):59. Epub 2010 Nov 12. PubMed PMID: 21074812.
Tagawa ST. Boning up on prognostic factors in advanced renal cell carcinoma. Ann Oncol 2011; 22: 751-3. PubMed PMID: 21447620.
Dubin JM, Chromecki TF, Beltran H, Goldenberg S, Cha EK, Karakiewicz PI, Zeltser IS, Scherr DS, Tagawa ST, Shariat SF. Management of Castration-Resistant Prostate Cancer in 2011. Ann Urol 2011 [Epub ahead of print]
Lee DJ, Cha EK, Dubin JM, Beltran H, Scherr DS, Tagawa ST, Shariat SF. Novel Therapeutics for the Management of Castration-Resistant Prostate Cancer. BJU Int 2012 Apr;109(7):968-85.doi: 10.1111/j.1464-410X.2011.10643.x. Epub 2011 Oct 28. Review. PubMed PMID: 22035221.
Tagawa ST, Beltran H. Abiraterone plus prednisone improves survival in metastatic castration resistant prostate cancer. As J Andrology 2011 Nov;13(6):785-6. doi: 10.1038/aja.2011.113. Epub 2011 Aug 22. PubMed PMID: 21857690.
Beltran H and Tagawa ST. Overview of disease pathways and drug targets. In Targeted Therapies for Castration-Resistant Prostate Cancer. Scardino PT Ed. Future Medicine, Ltd, 2011. doi:10.2217/EBO.11.72
Diamond E, Akhtar NH, Tagawa ST, Nanus DN. Chemotherapy in metastatic RCC: A targeted approach in non-clear-cell and sarcomatoid/rapidly progressive RCC. In Targeted Therapies for Renal Cell Carcinoma. Bukowski R Ed. Future Science Group, 2012.
Tagawa ST, Akhtar NH, Robinson BR, Beltran H. Uncommon Cancers of the Prostate. In Textbook of Uncommon Cancers, 4th Ed. Raghavan D et al. Eds. Wiley & Sons, Ltd, 2012. ISBN: 978-1-1180-8373-4
Beltran H, Tagawa S. Editorial Comment: “Detection of Metastatic Disease as A Leading Cause of Screening Failure in A Phase III Trial of Zibotentan Versus Placebo in Patients with Non-Metastatic Castration- Resistant Prostate Cancer (CRPC)”. J Urol 2012 Jul; 188(1): 108-9. Epub 2012 May 12.
Tagawa ST, Osborne J, Vallabhajosula V, Goldsmith SJ, Bander, NH. Prostate specific membrane antigen-based therapeutics. In Comprehensive Textbook of Prostate Cancer. Tewari A Ed. Springer, 2013.
Akhtar NH, Diamond ES, Eiseler N, Tagawa ST. Toxicity of androgen deprivation therapy in hormone sensitive prostate cancer. In Comprehensive Textbook of Prostate Cancer. Tewari A Ed. Springer, 2013.
Osborne J, Deh K, Anand A, Bander NH, Tagawa ST. Prostate specific membrane antigen-based diagnostics. In Comprehensive Textbook of Prostate Cancer. Tewari A Ed. Springer, 2013.
Akhtar NH, Basciano P, Parmar S, Tagawa ST. Cancer and Thrombosis. In Encyclopedia of Medical Immunology. Mackay IR and Rose NR Eds., Springer 2013. In press
Tagawa ST and Shariat SF. Opposing views: Is adjunctive systemic chemotherapy after cystectomy with T2N+ disease of therapeutic benefit? No. J Urol 2012 Aug; 188(2): 359-60.
Nanus DM, Tagawa ST. 2-weekly versus 3-weekly docetaxel for prostate cancer Lancet Oncol 2013 Jan 4. pii: S1470-2045(12)70579-X. doi: 10.1016/S1470-2045(12)70579-X. [Epub ahead of print]
Goldsmith SJ, Tagawa ST, Vallabhajosula V, Nikolopoulou A, Lipai I, Bander NH. Targeted radionuclide therapy of prostate cancer. In Medical Radiology. Brady LW, Heilmann HP, Hricak H, Knauth M, Molls M, Nieder C, Reiser MF, Eds., Springer 2013.
Balar A, Galsky M, Siefker-Radtke A. Tagawa ST, Milowsky MI. Chemotherapy. In Textbook of Upper Tract Urothelial Carcinoma. Xylinas E and Shariat S Eds., Springer 2013. In press
Diamond E, Riches J, Faltas B, Tagawa ST, Nanus DN. Immunologics and chemotherapeutics for renal cell carcinoma. Semin Intervent Radiol 2014; 31: 91-97.
Beltran H, Kaur G, de España CG, Tagawa ST. Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib. Asian J Androl. 2014 May 16. doi: 10.4103/1008-682X.127822. [Epub ahead of print]
Kaur G, Akhtar NH, Singh BK, Tagawa ST. Immunotherapy: Agents targeting prostate cancer. In Current Multidisciplinary Oncology. Dicker A, Trabulsi E, Kelly WK, Eds., Demos Medical Publishing, NY, 2014. In press
Tagawa ST. Neuroendocrine prostate cancer following hormonal therapy: Knowing is half the battle. Oncology Grand Rounds. J Clin Oncol 2014 Sept 15; Epub ahead of print
Diamond E, Garcias MC, Karir B, Tagawa ST. The evolving role of cytotoxic chemotherapy
in the management of patients with metastatic prostate cancer. Current Treatment Options in Oncology 2014; accepted
Honors and Awards
Deans List Scholar, Georgetown University College of Arts and Sciences Dean's List Scholar, 1989, 1992
Mid-Atlantic Academic All Conference Water Polo, Georgetown University, 1993
Dean's Scholar for the Junior/Senior Continuum, University of Southern California School of Medicine, 1998
Intern of the Year, USC Department of Medicine, 1999
Junior Resident of the Year, USC Department of Medicine, 2000
Senior Resident of the Year, USC Department of Medicine, 2001
Brautbar Teaching Award, USC Department of Medicine, 2001
Teacher of the Year, Division of Hematology, USC Department of Medicine, 2004
Chiron Immunotherapy Research Fellowship Award, 2004-05
Young Investigator Award, Prostate Cancer Foundation, 2008-2011
Super Doctors New York 2009, 2010, 2011, 2012, 2013, 2014
America's Top Doctors For Cancer, Volume 5
NIH Loan Repayment Program, Clinical Research (Extramural) 2009-2011
Top Doctors: New York Metro Area (13th Ed)
WCMC Department of Medicine Investigator Award Runner Up 2010
Guide to America’s Top Oncologists
Clinical Research, Loan Repayment Program Competitive Renewal, National Institutes of Health (Extramural)
America’s Top Doctors for Cancer, Volume 7
Top Doctors, US News & World Report 2011
America’s Top Doctors, 12th Ed.
Top Doctors: New York Metro Area, 17th Ed.
America’s Top Doctors, 13th Ed.
America’s Top Physicians (Castle-Connolly)
- Medical Oncology
- Urological Oncology
- Prostate Cancer
- Bladder Cancer
- Testicular Cancer
- Kidney Cancer
- Kidney or Bladder Cancer
- Urologic Cancer
Contact and Practices
- Internal Medicine
- Medical Oncology
- M.D., University of Southern California School of Medicine, 1998
- M.S., Weill Cornell Graduate School of Medical Sciences, 2010